English Polski
Vol 19 (2024): Continuous Publishing
Case report
Published online: 2024-06-12

open access

Page views 147
Article views/downloads 54
Get Citation

Connect on Social Media

Connect on Social Media

Cardio-Oncology Challenges - A Case Report of de novo Heart Failure in Tongue Cancer Patient

Piotr Fularski1, Maria Sawościan2, Małgorzata Lelonek2
DOI: 10.5603/fc.99223


Nowadays, the role of public education about cancer is increasing. Diagnostic methods are also being improved, which, coupled with increased patient awareness, translates into an increase in the detection of cancer and, therefore, an increased number of patients using oncological therapy. However, this therapy is not without complications, especially in the context of the cardiovascular system. It may lead to certain complications, such as cardiomyopathy, myocarditis, vascular damage, hypertension or the development of heart failure, as was the case in the described case. Even though some forms of therapy have a greater cardiotoxic potential than others. According to the ESC 2022 guidelines, each patient should undergo an appropriate cardiological assessment to determine the level of risk of developing cardiotoxic complications. This constitutes a specific challenge for doctors, and it is even more important because complications may appear even decades after the end of oncological therapy. The case presented below is intended to draw attention to the problems of cardio-oncology patients and contribute to their more effective diagnosis and treatment.

Article available in PDF format

View PDF Download PDF file


  1. Kostakou PM, Kouris NT, Kostopoulos VS, et al. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2019; 24(1): 91–100.
  2. Choksey A, Timm KN. Cancer therapy-induced cardiotoxicity-a metabolic perspective on pathogenesis, diagnosis and therapy. Int J Mol Sci. 2021; 23(1): 441.
  3. Lyon AR, López-Fernández T, Couch LS, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
  4. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720–1729.
  5. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(2): 137–155.
  6. Didkowska J, Wojciechowska U, Michalek IM, et al. Cancer incidence and mortality in Poland in 2019. Sci Rep. 2022; 12(1): 10875.
  7. Dreyfuss AD, Velalopoulou A, Avgousti H, et al. Preclinical models of radiation-induced cardiac toxicity: potential mechanisms and biomarkers. Front Oncol. 2022; 12: 920867.
  8. Upshaw JN. Cardio-oncology: protecting the heart from curative breast cancer treatment. Gland Surg. 2018; 7(4): 350–365.
  9. Upshaw J. HFpEF After Cancer Therapy. American College of Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/10/26/13/08/hfpef-after-cancer-therapy (03.06.2024).
  10. Stępień K, Del Carmen Yika A, Bilecki K, et al. Multiple late cardiovascular complications after combined oncological treatment of Hodgkin's lymphoma. Kardiol Pol. 2023; 81(1): 78–79.
  11. Nessler J, Krawczyk K, Leszek P, et al. Opinia ekspertów Asocjacji Niewydolności Serca Polskiego Towarzystwa Kardiologicznego, Kolegium Lekarzy Rodzinnych W Polsce oraz Polskiego Towarzystwa Medycyny Rodzinnej dotycząca postępowania w okresie okołowypisowym u pacjentów z niewydolnością serca. Zeszyty edukacyjne. Kardiologia Polska. 2022; 2: 34–56.
  12. Chiang CH, Chiang CH, Chiang CH, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023; 109(6): 470–477.
  13. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44(37): 3627–3639.
  14. Belsky JA, Yeager ND, Fitch J, et al. Case of severe cardiotoxicity in a pediatric patient after fluorouracil administration. JCO Precis Oncol. 2019; 3: 1–4.